593 related articles for article (PubMed ID: 21308679)
21. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
22. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
23. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance.
Shen SS; Lerner SP; Muezzinoglu B; Truong LD; Amiel G; Wheeler TM
Hum Pathol; 2006 Jun; 37(6):726-34. PubMed ID: 16733214
[TBL] [Abstract][Full Text] [Related]
24. When intravesical measures fail. Indications for cystectomy in superficial disease.
Hudson MA
Urol Clin North Am; 1992 Aug; 19(3):601-9. PubMed ID: 1636242
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of superficial bladder cancer.
Amling CL
Curr Probl Cancer; 2001; 25(4):219-78. PubMed ID: 11514784
[TBL] [Abstract][Full Text] [Related]
26. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.
Ovesen H; Poulsen AL; Steven K
Br J Urol; 1993 Nov; 72(5 Pt 2):744-8. PubMed ID: 8281407
[TBL] [Abstract][Full Text] [Related]
27. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
28. Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder.
Tongaonkar HB; Dalal AV; Kulkarni JN; Kamat MR
Br J Urol; 1993 Dec; 72(6):910-4. PubMed ID: 8306154
[TBL] [Abstract][Full Text] [Related]
29. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
30. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
31. Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
Canda AE; Tuzel E; Mungan MU; Yorukoglu K; Kirkali Z
Eur Urol; 2004 Apr; 45(4):465-9; discussion 469-70. PubMed ID: 15041110
[TBL] [Abstract][Full Text] [Related]
32. Superficial urothelial cancer in the prostatic urethra.
Kirkali Z; Canda AE
ScientificWorldJournal; 2006 Feb; 6():2603-10. PubMed ID: 17619737
[TBL] [Abstract][Full Text] [Related]
33. [T1 G3 bladder tumors: the respective role of BCG and cystectomy].
Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H
Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369
[TBL] [Abstract][Full Text] [Related]
34. [Urethral recurrence after cysto-prostatectomy for bladder tumor].
Robert M; Burgel JS; Serre I; Guiter J; Grasset D
Prog Urol; 1996; 6(4):558-63. PubMed ID: 8924933
[TBL] [Abstract][Full Text] [Related]
35. Urethral involvement in female patients with bladder cancer. A study of 22 cystectomy specimens.
De Paepe ME; André R; Mahadevia P
Cancer; 1990 Mar; 65(5):1237-41. PubMed ID: 2302672
[TBL] [Abstract][Full Text] [Related]
36. Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG.
Orihuela E; Herr HW; Whitmore WF
Urology; 1989 Nov; 34(5):231-7. PubMed ID: 2815442
[TBL] [Abstract][Full Text] [Related]
37. Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer.
Ingram JW; Chung R; Laplaca C; McKiernan JM; Lenis AT; Anderson CB
Urol Oncol; 2024 Sep; 42(9):290.e11-290.e16. PubMed ID: 38688797
[TBL] [Abstract][Full Text] [Related]
38. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
39. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
40. [Transitional cell carcinoma of the urethra in patients after cystectomy for bladder carcinoma].
Marino G; Marten Perolino R
Minerva Urol Nefrol; 1992; 44(3):209-12. PubMed ID: 1492273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
